TriSalus Life Sciences, Inc. Operating Cash Flow
TriSalus Life Sciences, Inc. (TLSI) reported Operating Cash Flow of -$16.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.13M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.48M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.48M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.71M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$18.01M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$40.84M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$50.58M.
- TriSalus Life Sciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$32.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 4 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$16.61M 10-Q · filed 2026-08-06 | -$19.09M derived: sum of 3 quarters · filed 2026-08-06 | -$22.80M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2026-03-31 | -$6.48M 10-Q · filed 2026-05-12 | -$8.96M derived: sum of 2 quarters · filed 2026-05-12 | -$12.67M derived: sum of 3 quarters · filed 2026-05-12 | -$19.99M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-12-31 | -$2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$6.19M derived: sum of 2 quarters · filed 2026-03-05 | -$13.51M derived: sum of 3 quarters · filed 2026-08-06 | -$18.01M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | -$3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.03M derived: sum of 2 quarters · filed 2026-08-06 | -$15.53M 10-Q · filed 2025-11-13 | -$21.23M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-06-30 | -$7.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$11.82M 10-Q · filed 2026-08-06 | -$17.53M derived: sum of 3 quarters · filed 2026-08-06 | -$28.37M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-03-31 | -$4.50M 10-Q · filed 2026-05-12 | -$10.21M derived: sum of 2 quarters · filed 2026-05-12 | -$21.05M derived: sum of 3 quarters · filed 2026-05-12 | -$34.48M derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | -$5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$16.55M derived: sum of 2 quarters · filed 2026-03-05 | -$29.98M derived: sum of 3 quarters · filed 2026-03-05 | -$40.84M 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | -$10.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$24.27M derived: sum of 2 quarters · filed 2025-11-13 | -$35.14M 10-Q · filed 2025-11-13 | -$44.31M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$13.42M derived: 10-Q 6 month − 10-K/A 3 month · filed 2025-08-12 | -$24.29M 10-Q · filed 2025-08-12 | -$33.47M derived: sum of 3 quarters · filed 2025-08-12 | -$55.13M derived: sum of 4 quarters · filed 2025-08-12 | |||||
| 2024-03-31 | -$10.87M 10-K/A · filed 2025-05-30 | -$20.04M derived: sum of 2 quarters · filed 2025-05-30 | -$41.71M derived: sum of 3 quarters · filed 2025-05-30 | -$50.94M derived: sum of 4 quarters · filed 2025-05-30 | |||||
| 2023-12-31 | -$9.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-05-30 | -$30.84M derived: sum of 2 quarters · filed 2025-05-30 | -$40.08M derived: sum of 3 quarters · filed 2025-05-30 | -$50.58M 10-K/A · filed 2025-05-30 | -$50.05M 10-K · filed 2024-04-11 | ||||
| 2023-09-30 | -$21.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$30.90M derived: sum of 2 quarters · filed 2024-11-14 | -$41.40M 10-Q · filed 2024-11-14 | -$41.20M 10-Q · filed 2023-11-14 | -$49.71M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$19.74M 10-Q · filed 2024-08-14 | -$1.01M 10-Q · filed 2023-08-02 | -$28.05M derived: sum of 3 quarters · filed 2024-08-14 | -$50.93M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$10.50M 10-Q · filed 2024-05-15 | -$698.41K 10-Q · filed 2023-05-12 | -$18.81M derived: sum of 2 quarters · filed 2024-05-15 | -$41.69M derived: sum of 3 quarters · filed 2024-05-15 | -$42.39M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | -$31.19M derived: sum of 2 quarters · filed 2024-04-11 | -$31.89M derived: sum of 3 quarters · filed 2024-04-11 | -$32.31M 10-K · filed 2024-04-11 | -$2.74M 10-K · filed 2023-03-22 | ||||
| 2022-09-30 | -$22.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$23.58M derived: sum of 2 quarters · filed 2023-11-14 | -$24.00M 10-Q · filed 2023-11-14 | -$1.47M 10-Q · filed 2022-11-10 | -$24.68M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$696.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$1.12M 10-Q · filed 2023-08-02 | -$1.80M derived: sum of 3 quarters · filed 2023-08-02 | -$2.17M derived: sum of 4 quarters · filed 2023-08-02 | |||||
| 2022-03-31 | -$425.95K 10-Q · filed 2023-05-12 | -$1.11M derived: sum of 2 quarters · filed 2023-05-12 | -$1.47M derived: sum of 3 quarters · filed 2023-05-12 | -$1.96M derived: sum of 4 quarters · filed 2023-05-12 | |||||
| 2021-12-31 | -$680.92K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$1.05M derived: sum of 2 quarters · filed 2023-03-22 | -$1.53M derived: sum of 3 quarters · filed 2023-03-22 | -$1.74M 10-K · filed 2023-03-22 | |||||
| 2021-09-30 | -$365.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$851.35K derived: sum of 2 quarters · filed 2022-11-10 | -$1.06M 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | -$486.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$692.05K 10-Q · filed 2022-08-10 | |||||||
| 2021-03-31 | -$205.85K 10-Q · filed 2022-05-11 | ||||||||
| 2020-12-31 | -$677.60K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |